ClinicalTrials.gg
CompletedNCT06627478Updated Oct 23, 2026Results posted

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®

A Phase 1 interventional study of NKF-INS(G) and US-Lantus® in Healthy Participants, sponsored by Xentria, Inc.. Completed at 1 site in South Africa. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Xentria, Inc. · Phase 1, Interventional, and Other

Updated Oct 23, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

Single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®

Read the detailed description

A single center, single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS(G), US-Lantus®, and EU-Lantus® using the euglycemic clamp technique in healthy male adult volunteers

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Xentria, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated obtained before any trial-related activities. Trial-related activities are any procedures that would not have been done during normal management of the participant.
  2. Healthy male participants
  3. Age between 18 and 50 years, both inclusive
  4. between 18.5 and 29.0 kg/m2, both inclusive
  5. Body weight ≥ 59 kg
  6. Fasting glucose concentration ≤ 5.5 mmol/L at screening
  7. Considered generally healthy upon completion of medical history, physical examination, vital signs, (ECG), and analysis of laboratory safety variables, as judged by the Investigator
  8. Willing and able to comply with scheduled visits, treatment plan, clinical laboratory tests, and other study procedures including lifestyle considerations.
  9. Participants must agree to use condoms during sexual intercourse. Additionally, female partners of male participants should use highly effective . All contraceptive measures apply from screening until 90 days after study treatment. Male participants must refrain from donating or banking sperm for 90 days after administration of study treatment.
  10. Have competence in speaking, writing, and comprehending the local language(s) where the study is conducted.

Exclusion criteria

Exclusion Criteria:

  1. Positive for human insulin antibodies at Screening
  2. Are currently enrolled in or have discontinued within 3 months or 5 half-lives (whichever is longer) of any drug or device or are concurrently enrolled in any other type of medical research study and judged not to be scientifically or medically compatible with this study.
  3. Have known allergies to insulin, its , or related drugs or have history of relevant allergic reactions of any origin, or any specific investigational product safety concern.
  4. History of diabetes mellitus; episodes of hypoglycemia in the anamnesis; any history of insulin use for treatment purposes.
  5. Have history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data.
  6. Increased risk of thrombosis, e.g., individuals with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.
  7. Clinically significant abnormal at screening.
  8. Glycemia level ≥140 mg/dL 2 hours after the glucose load.
  9. Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
  10. Positive urine drug test at screening and/or evidence of current use of known drugs of abuse or have a history of use within the past year.
  11. Show evidence of an acute infection with fever or infectious disease at the time of enrollment.
  12. Show evidence of (HIV) infection and/or positive human HIV antibodies at screening.
  13. Have positive test results for surface antigen (HBsAg), immunoglobulin M (IgM) antibody to hepatitis B core antigen (anti-HBc), or virus (HCV) antibodies at screening.
  14. Intend to use over-the-counter medication within 7 days or prescription medication within 14 days prior to dosing (apart from vitamin/mineral supplements, occasional paracetamol, thyroid replacement).
  15. Have donated blood or had a blood loss of 500 mL 3 months prior to study enrollment.
  16. Have an average weekly alcohol intake that exceeds 21 units per week or is unwilling to stop alcohol consumption from 48 hours prior to each dosing until being discharged from the Clinical Research Unit (CRU).
  17. Employees or close relatives of the Sponsor, contract research organization (CRO), third-party vendors. or affiliates of the above-mentioned parties.
  18. Inadequate venous access.
  19. Vulnerable populations, e.g., persons in detention.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Active comparator
    United States (US)-Lantus®

    Single subcutaneous dose administered over three treatment periods

    Drug: US-Lantus®

  • Active comparator
    European Union (EU)-Lantus®

    Single subcutaneous dose administered over three treatment periods

    Drug: EU-Lantus®

  • Experimental
    NKF-INS Glargine (G)

    Single subcutaneous dose administered over three treatment periods

    Drug: NKF-INS(G)

Interventions

  • DrugNKF-INS(G)

    Single subcutaneous dose of 0.5 IU/kg administered over three periods

  • DrugUS-Lantus®

    Single subcutaneous dose of 0.5 IU/kg administered over three periods

  • DrugEU-Lantus®

    Single subcutaneous dose of 0.5 IU/kg administered over three periods

06

What researchers measure

Primary outcomes

  1. Area Under the M1 Concentration-Time Curve From 0 to 12 Hours (AUC0-12h of M1)

    Compared the pharmacokinetics (PK) of NKF-INS Glargine(G) to United States (US)-approved and European Union (EU)-authorized Lantus to demonstrate PK similarity for metabolite 21A-Gly-human insulin (M1)

    Time frame: 0 to 12 hours post-dose

Secondary outcomes

  1. Maximum Capacity (Cmax) of M1

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 0 to 24 hours post-dose

  2. Area Under the Concentration-Time Curve AUC0-6h, AUC6-12h and AUC0-12h of M1

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 0 to 12 hours post-dose

  3. Area Under the Concentration-Time Curve AUC12-18h and AUC12-24h of M1

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 12 to 24 hours post-dose

  4. Area Under the Concentration-Time Curve AUC18-24h of M1

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 18 to 24 hours post-dose

  5. Time to Maximum Concentration (Tmax) of M1

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 0 to 24 hours post-dose

  6. Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of M1

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 0 to 24 hours post-dose

  7. Maximum Concentration (Cmax) of Insulin Glargine

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 0 to 24 hours post-dose

  8. Area Under the Concentration-Time Curve AUC0-12h and AUC0-24h of Insulin Glargine

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 0 to 24 hours post-dose

  9. Area Under the Concentration-Time Curve AUC0-6hr of Insulin Glargine

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 0 to 6 hours post-dose

  10. Area Under the Concentration-Time Curve AUC6-12h of Insulin Glargine

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 6 to 12 hours post-dose

  11. Area Under the Concentration-Time Curve AUC12-18h of Insulin Glargine

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 12 to 18 hours post-dose

  12. Area Under the Concentration-Time Curve AUC18-24h of Insulin Glargine

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 18 to 24 hours post-dose

  13. Area Under the Concentration-Time Curve AUC12-24h of Insulin Glargine

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 12 to 24 hours post-dose

  14. Time to Maximum Concentration (Tmax) of Insulin Glargine

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 0 to 24 hours post-dose

  15. Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Insulin Glargine

    Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

    Time frame: 0 to 24 hours post-dose

  16. GIRAUC0-24h, GIRAUC0-end of Clamp up to 24hours, GIRAUC0-6h, GIRAUC0-12h

    Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies

    Time frame: 0 to 24 hours post-dose

  17. GIRAUC0-∞

    Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies

    Time frame: 0 to 24 hours post-dose

  18. GIRAUC6-12h

    Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies

    Time frame: 6 to 12 hours post-dose

  19. GIRAUC12-18h and GIRAUC12-24h

    Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies

    Time frame: 12 to 24 hours post-dose

  20. GIRAUC18-24h

    Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies

    Time frame: 18 to 24 hours post-dose

  21. GIRmax

    Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.

    Time frame: 0 to 24 hours post-dose

  22. Time to GIRmax

    Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.

    Time frame: 0 to 24 hours post-dose

  23. Total Amount of Glucose Infused During Clamp Procedure (Gtot)

    Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.

    Time frame: 0 to 24 hours post-dose

07

Results

Posted Oct 23, 2026

Participant flow

Participant flow — Overall Study
MilestoneNKF-INS(G), EU-Lantus, US-LantusNKF-INS(G), US-Lantus, EU-LantusEU-Lantus, NKF-INS(G), US-LantusEU-Lantus, US-Lantus, NKF-INS(G)US-Lantus, NKF-INS(G), EU-LantusUS-Lantus, EU-Lantus, NKF-INS(G)
Started191919191919
Completed181819191819
Not completed110010

Outcome measures

PrimaryArea Under the M1 Concentration-Time Curve From 0 to 12 Hours (AUC0-12h of M1)

Compared the pharmacokinetics (PK) of NKF-INS Glargine(G) to United States (US)-approved and European Union (EU)-authorized Lantus to demonstrate PK similarity for metabolite 21A-Gly-human insulin (M1)

Time frame:
0 to 12 hours post-dose
Reported as:
Geometric mean · hours*ng/mL
Area Under the M1 Concentration-Time Curve From 0 to 12 Hours (AUC0-12h of M1)
hours*ng/mLUS-Lantus®NKF-INS(G)EU-Lantus®
Area Under the M1 Concentration-Time Curve From 0 to 12 Hours (AUC0-12h of M1)7.970 ± 32.4797.781 ± 33.4287.564 ± 33.488
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio]: 102.914 · 90% CI 96.886 to 109.318
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 97.723 · 90% CI 93.153 to 102.518
SecondaryMaximum Capacity (Cmax) of M1

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Capacity (Cmax) of M1
ng/mLUS-Lantus®NKF-INS(G)EU-Lantus®
Maximum Capacity (Cmax) of M1.455 ± 30.623.450 ± 33.288.433 ± 31.454
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 104.080 · 90% CI 98.460 to 110.021
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 98.920 · 90% CI 94.144 to 103.939
SecondaryArea Under the Concentration-Time Curve AUC0-6h, AUC6-12h and AUC0-12h of M1

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
0 to 12 hours post-dose
Reported as:
Geometric mean · hours*ng/mL
Area Under the Concentration-Time Curve AUC0-6h, AUC6-12h and AUC0-12h of M1
hours*ng/mLUS-Lantus®NKF-INS(G)EU-Lantus®
AUC0-6h of M11.715 ± 32.3421.568 ± 38.6121.584 ± 32.554
AUC6-12h of M11.782 ± 41.5231.767 ± 42.4311.723 ± 37.567
AUC0-12h of M14.082 ± 32.4803.875 ± 36.7023.845 ± 32.363
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 99.088 · 90% CI 93.876 to 104.589
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 91.546 · 90% CI 87.143 to 96.172
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 102.595 · 90% CI 95.413 to 110.318
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 99.210 · 90% CI 92.479 to 106.431
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 100.841 · 90% CI 95.197 to 106.821
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 95.022 · 90% CI 90.269 to 100.025
SecondaryArea Under the Concentration-Time Curve AUC12-18h and AUC12-24h of M1

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
12 to 24 hours post-dose
Reported as:
Geometric mean · hours*ng/mL
Area Under the Concentration-Time Curve AUC12-18h and AUC12-24h of M1
hours*ng/mLUS-Lantus®NKF-INS(G)EU-Lantus®
AUC12-18h of M11.675 ± 28.5591.582 ± 41.9391.571 ± 33.503
AUC12-24h of M13.322 ± 27.4493.165 ± 43.0013.222 ± 30.522
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 99.980 · 90% CI 93.092 to 107.377
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 95.201 · 90% CI 89.704 to 101.035
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 97.627 · 90% CI 91.529 to 104.131
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 96.702 · 90% CI 91.906 to 101.749
SecondaryArea Under the Concentration-Time Curve AUC18-24h of M1

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
18 to 24 hours post-dose
Reported as:
Geometric mean · hours*ng/mL
Area Under the Concentration-Time Curve AUC18-24h of M1
hours*ng/mLUS-Lantus®NKF-INS(G)EU-Lantus®
Area Under the Concentration-Time Curve AUC18-24h of M11.105 ± 51.3671.101 ± 43.5701.148 ± 35.329
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 93.446 · 90% CI 86.912 to 100.471
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 99.451 · 90% CI 90.813 to 108.911
SecondaryTime to Maximum Concentration (Tmax) of M1

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · hours
Time to Maximum Concentration (Tmax) of M1
hoursUS-Lantus®NKF-INS(G)EU-Lantus®
Time to Maximum Concentration (Tmax) of M19.867 ± 47.51110.823 ± 39.0939.537 ± 58.511
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 113.356 · 90% CI 102.255 to 125.663
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 109.761 · 90% CI 100.813 to 119.504
SecondaryArea Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of M1

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · hours*ng/ml
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of M1
hours*ng/mlUS-Lantus®NKF-INS(G)EU-Lantus®
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of M112.250 ± 19.31713.567 ± 18.41412.352 ± 22.818
SecondaryMaximum Concentration (Cmax) of Insulin Glargine

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · pg/mL
Maximum Concentration (Cmax) of Insulin Glargine
pg/mLUS-Lantus®NKF-INS(G)EU-Lantus®
Maximum Concentration (Cmax) of Insulin Glargine193.763 ± 38.721188.896 ± 38.449186.117 ± 31.301
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 103.127 · 90% CI 97.131 to 109.492
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 97.758 · 90% CI 92.371 to 103.460
SecondaryArea Under the Concentration-Time Curve AUC0-12h and AUC0-24h of Insulin Glargine

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · hours*pg/mL
Area Under the Concentration-Time Curve AUC0-12h and AUC0-24h of Insulin Glargine
hours*pg/mLUS-Lantus®NKF-INS(G)EU-Lantus®
AUC0-12h of insulin glargine836.127 ± 163.281793.846 ± 183.945791.192 ± 136.684
AUC0-24h of insulin glargine1115.563 ± 192.3531169.504 ± 171.2601062.236 ± 156.306
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 98.532 · 90% CI 77.948 to 124.553
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 94.227 · 90% CI 76.551 to 115.985
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 110.411 · 90% CI 89.433 to 136.309
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 104.219 · 90% CI 83.171 to 130.593
SecondaryArea Under the Concentration-Time Curve AUC0-6hr of Insulin Glargine

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
0 to 6 hours post-dose
Reported as:
Geometric mean · hours*pg/mL
Area Under the Concentration-Time Curve AUC0-6hr of Insulin Glargine
hours*pg/mLUS-Lantus®NKF-INS(G)EU-Lantus®
Area Under the Concentration-Time Curve AUC0-6hr of Insulin Glargine512.697 ± 116.596457.218 ± 128.758458.443 ± 102.241
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 101.279 · 90% CI 85.293 to 120.261
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 88.645 · 90% CI 75.407 to 104.206
SecondaryArea Under the Concentration-Time Curve AUC6-12h of Insulin Glargine

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
6 to 12 hours post-dose
Reported as:
Geometric mean · hours*pg/mL
Area Under the Concentration-Time Curve AUC6-12h of Insulin Glargine
hours*pg/mLUS-Lantus®NKF-INS(G)EU-Lantus®
Area Under the Concentration-Time Curve AUC6-12h of Insulin Glargine536.777 ± 51.377549.668 ± 49.277506.895 ± 53.693
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 108.784 · 90% CI 95.182 to 124.329
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 103.597 · 90% CI 92.463 to 116.071
SecondaryArea Under the Concentration-Time Curve AUC12-18h of Insulin Glargine

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
12 to 18 hours post-dose
Reported as:
Geometric mean · hours*pg/mL
Area Under the Concentration-Time Curve AUC12-18h of Insulin Glargine
hours*pg/mLUS-Lantus®NKF-INS(G)EU-Lantus®
Area Under the Concentration-Time Curve AUC12-18h of Insulin Glargine287.389 ± 127.986302.907 ± 69.204326.417 ± 69.138
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 94.152 · 90% CI 70.353 to 126.003
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 100.263 · 90% CI 76.281 to 131.783
SecondaryArea Under the Concentration-Time Curve AUC18-24h of Insulin Glargine

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
18 to 24 hours post-dose
Reported as:
Geometric mean · hours*pg/mL
Area Under the Concentration-Time Curve AUC18-24h of Insulin Glargine
hours*pg/mLUS-Lantus®NKF-INS(G)EU-Lantus®
Area Under the Concentration-Time Curve AUC18-24h of Insulin Glargine319.948 ± 79.932215.605 ± 98.843226.813 ± 164.522
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 71.349 · 90% CI 7.968 to 638.895
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 61.962 · 90% CI 8.360 to 459.244
SecondaryArea Under the Concentration-Time Curve AUC12-24h of Insulin Glargine

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
12 to 24 hours post-dose
Reported as:
Geometric mean · hours*pg/mL
Area Under the Concentration-Time Curve AUC12-24h of Insulin Glargine
hours*pg/mLUS-Lantus®NKF-INS(G)EU-Lantus®
Area Under the Concentration-Time Curve AUC12-24h of Insulin Glargine374.189 ± 158.113387.468 ± 99.751450.063 ± 96.891
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 85.329 · 90% CI 62.182 to 117.094
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 98.121 · 90% CI 72.070 to 133.588
SecondaryTime to Maximum Concentration (Tmax) of Insulin Glargine

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · hours
Time to Maximum Concentration (Tmax) of Insulin Glargine
hoursUS-Lantus®NKF-INS(G)EU-Lantus®
Time to Maximum Concentration (Tmax) of Insulin Glargine1.545 ± 157.9861.907 ± 170.4861.534 ± 157.958
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 122.302 · 90% CI 93.085 to 160.690
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 122.524 · 90% CI 95.011 to 158.003
SecondaryArea Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Insulin Glargine

Evaluated additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargine and/or M1.

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · hours*ng/ml
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Insulin Glargine
hours*ng/mlUS-Lantus®NKF-INS(G)EU-Lantus®
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Insulin Glargine5440.993 ± 58.9605987.074 ± 59.1275673.057 ± 80.945
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 100.408 · 90% CI 76.416 to 131.933
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 119.199 · 90% CI 98.664 to 144.007
SecondaryGIRAUC0-24h, GIRAUC0-end of Clamp up to 24hours, GIRAUC0-6h, GIRAUC0-12h

Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · min*mg/min
GIRAUC0-24h, GIRAUC0-end of Clamp up to 24hours, GIRAUC0-6h, GIRAUC0-12h
min*mg/minUS-Lantus®NKF-INS(G)EU-Lantus®
GIRAUC0-24h198256.821 ± 47.267200966.263 ± 41.906187594.648 ± 46.027
GIRAUC0-end of clamp up to 24h198256.821 ± 47.267200966.263 ± 41.906187594.648 ± 46.027
GIRAUC0-6h33586.896 ± 52.47032444.949 ± 46.86832294.837 ± 38.298
GIRAUC0-12h103441.058 ± 42.081102868.998 ± 38.48298785.375 ± 35.280
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 107.018 · 95% CI 99.979 to 114.552
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 101.408 · 90% CI 96.387 to 106.690
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 107.018 · 95% CI 99.979 to 114.552
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 101.408 · 90% CI 96.387 to 106.690
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 100.404 · 95% CI 93.542 to 107.769
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 96.720 · 90% CI 90.259 to 103.643
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 104.094 · 95% CI 98.357 to 110.166
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 99.515 · 90% CI 94.510 to 104.786
SecondaryGIRAUC0-∞

Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · min*mg/min
GIRAUC0-∞
min*mg/minUS-Lantus®NKF-INS(G)EU-Lantus®
GIRAUC0-∞201674.663 ± 57.803208064.846 ± 55.531197857.889 ± 57.928
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 102.796 · 95% CI 88.750 to 119.065
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 103.140 · 90% CI 91.706 to 115.999
SecondaryGIRAUC6-12h

Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies

Time frame:
6 to 12 hours post-dose
Reported as:
Geometric mean · min*mg/min
GIRAUC6-12h
min*mg/minUS-Lantus®NKF-INS(G)EU-Lantus®
GIRAUC6-12h67272.256 ± 45.09168561.314 ± 37.82765410.503 ± 36.943
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 105.508 · 95% CI 98.993 to 112.453
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 101.963 · 90% CI 96.328 to 107.927
SecondaryGIRAUC12-18h and GIRAUC12-24h

Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies

Time frame:
12 to 24 hours post-dose
Reported as:
Geometric mean · min*mg/min
GIRAUC12-18h and GIRAUC12-24h
min*mg/minUS-Lantus®NKF-INS(G)EU-Lantus®
GIRAUC12-18h58633.790 ± 42.09357219.839 ± 60.36855497.942 ± 52.951
GIRAUC12-24h95634.920 ± 46.92992197.484 ± 71.17889431.857 ± 60.379
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 103.453 · 95% CI 92.837 to 115.283
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 100.416 · 90% CI 95.229 to 105.885
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 103.654 · 95% CI 92.259 to 116.456
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 99.912 · 90% CI 94.690 to 105.423
SecondaryGIRAUC18-24h

Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose. Glucose infusion rate (GIR) was recorded in mg/min throughout the clamp procedure. The area under the GIR-vs-time curve (GIRAUC) was calculated by integrating GIR (mg/min) over time (min). Consistent with the finalized Clinical Study Report and prior trials in this program, the resulting unit is expressed as min\*mg/min to explicitly denote the time-integration of the rate variable, rather than simplifying to the mathematically equivalent unit of mg. This notation reflects that GIRAUC represents the integral of an infusion rate over the study duration, consistent with standard reporting conventions for glucose clamp studies

Time frame:
18 to 24 hours post-dose
Reported as:
Geometric mean · min*mg/min
GIRAUC18-24h
min*mg/minUS-Lantus®NKF-INS(G)EU-Lantus®
GIRAUC18-24h34730.926 ± 79.97434497.876 ± 83.64732877.898 ± 72.987
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 101.930 · 95% CI 92.124 to 112.780
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 99.297 · 90% CI 90.364 to 109.113
SecondaryGIRmax

Compared the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · mg/min
GIRmax
mg/minUS-Lantus®NKF-INS(G)EU-Lantus®
GIRmax242.738 ± 39.069239.782 ± 35.090232.469 ± 35.694
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 103.058 · 95% CI 97.301 to 109.156
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 98.799 · 90% CI 93.993 to 103.852
SecondaryTime to GIRmax

Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · min
Time to GIRmax
minUS-Lantus®NKF-INS(G)EU-Lantus®
Time to GIRmax563.411 ± 36.457600.146 ± 30.112530.081 ± 43.786
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 112.889 · 95% CI 103.004 to 123.722
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 106.525 · 90% CI 100.043 to 113.426
SecondaryTotal Amount of Glucose Infused During Clamp Procedure (Gtot)

Compared the pharmacodynamics (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.

Time frame:
0 to 24 hours post-dose
Reported as:
Geometric mean · mg/kg
Total Amount of Glucose Infused During Clamp Procedure (Gtot)
mg/kgUS-Lantus®NKF-INS(G)EU-Lantus®
Total Amount of Glucose Infused During Clamp Procedure (Gtot)198256.821 ± 47.267200966.263 ± 41.906187594.648 ± 46.027
Statistical analysis
  • NKF-INS(G) vs EU-Lantus® · Geometric mean ratio: 107.018 · 95% CI 99.979 to 114.552
  • US-Lantus® vs NKF-INS(G) · Geometric mean ratio: 101.408 · 90% CI 96.387 to 106.690

Adverse events

Collected over Day 1 to EOS visit (2-11 days after last administration of study drug), up to 7 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
United States (US)-Lantus®0/113 (0%)0/113 (0%)20/113 (17.7%)
NKF-INS Glargine (G)0/114 (0%)0/114 (0%)20/114 (17.5%)
European Union (EU)-Lantus®0/111 (0%)0/111 (0%)31/111 (27.9%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventUnited States (US)-Lantus®NKF-INS Glargine (G)European Union (EU)-Lantus®
HeadacheNervous system disorders7/1139/1146/111
Infusion site swellingGeneral disorders1/1136/1145/111
Injection site painGeneral disorders5/1131/1145/111
DizzinessNervous system disorders2/1131/1143/111
InfluenzaInfections and infestations0/1130/1143/111
Infusion site painGeneral disorders1/1130/1142/111
DiarrhoeaGastrointestinal disorders0/1131/1142/111
Soft tissue injuryInjury, poisoning and procedural complications0/1130/1142/111
Blood creatine phosphokinase increasedInvestigations2/1130/1140/111
Injection site pruritusGeneral disorders1/1132/1140/111

Baseline characteristics

Age, Customized
Age, Customized(years)NKF-INS(G), EU-Lantus, US-LantusNKF-INS(G), US-Lantus, EU-LantusEU-Lantus, NKF-INS(G), US-LantusEU-Lantus, US-Lantus, NKF-INS(G)US-Lantus, NKF-INS(G), EU-LantusUS-Lantus, EU-Lantus, NKF-INS(G)Total
Mean32.16 ± 8.5531.53 ± 6.7531.16 ± 7.8134.21 ± 7.0232.79 ± 8.4829.74 ± 5.7631.93 ± 7.43
Sex/Gender, Customized
Sex/Gender, Customized(Participants)NKF-INS(G), EU-Lantus, US-LantusNKF-INS(G), US-Lantus, EU-LantusEU-Lantus, NKF-INS(G), US-LantusEU-Lantus, US-Lantus, NKF-INS(G)US-Lantus, NKF-INS(G), EU-LantusUS-Lantus, EU-Lantus, NKF-INS(G)Total
Male191919191919114
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NKF-INS(G), EU-Lantus, US-LantusNKF-INS(G), US-Lantus, EU-LantusEU-Lantus, NKF-INS(G), US-LantusEU-Lantus, US-Lantus, NKF-INS(G)US-Lantus, NKF-INS(G), EU-LantusUS-Lantus, EU-Lantus, NKF-INS(G)Total
Black or African American15181615151897
Other1121207
White30132110
BMI
BMI(kg/m^2)NKF-INS(G), EU-Lantus, US-LantusNKF-INS(G), US-Lantus, EU-LantusEU-Lantus, NKF-INS(G), US-LantusEU-Lantus, US-Lantus, NKF-INS(G)US-Lantus, NKF-INS(G), EU-LantusUS-Lantus, EU-Lantus, NKF-INS(G)Total
Mean23.87 ± 2.6124.48 ± 2.6823.76 ± 2.6525.03 ± 2.5924.57 ± 2.1725.9 ± 2.3124.6 ± 2.56
Height (cm)
Height (cm)(cm)NKF-INS(G), EU-Lantus, US-LantusNKF-INS(G), US-Lantus, EU-LantusEU-Lantus, NKF-INS(G), US-LantusEU-Lantus, US-Lantus, NKF-INS(G)US-Lantus, NKF-INS(G), EU-LantusUS-Lantus, EU-Lantus, NKF-INS(G)Total
Mean175.08 ± 6.64171.94 ± 5.91172.72 ± 6.33173.69 ± 7.01171.85 ± 6.03169.81 ± 6.42172.51 ± 6.47
Weight
Weight(kg)NKF-INS(G), EU-Lantus, US-LantusNKF-INS(G), US-Lantus, EU-LantusEU-Lantus, NKF-INS(G), US-LantusEU-Lantus, US-Lantus, NKF-INS(G)US-Lantus, NKF-INS(G), EU-LantusUS-Lantus, EU-Lantus, NKF-INS(G)Total
Mean73.16 ± 9.1872.48 ± 9.4870.94 ± 9.2975.4 ± 8.0772.59 ± 7.4474.96 ± 10.3273.25 ± 8.94
08

Study locations

1 site
  • FARMOVS Clinical Research Organisation
    Bloemfontein, 9301, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jul 2025, 8 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 4, 2024
StartActual
Oct 29, 2024
Primary completionActual
Jul 3, 2025
CompletionActual
Jul 3, 2025
Results first posted
Oct 23, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 23, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore To compare the Pharmacokinetic (PK) of NKF-INS Glargine(G) to United States (US)-approved and European Union (EU)-authorized Lantus to demonstrate PK similarity for metabolite 21A-Gly-human insulin (M1)Now Area Under the M1 Concentration-Time Curve From 0 to 12 Hours (AUC0-12h of M1)Time frame: 60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose → 0 to 12 hours post-dose
Oct 23, 2026
Documents
Secondary outcomes
23 added, 4 removed
What changed in the outcomes
  • AddedMaximum Capacity (Cmax) of M1Time frame: 0 to 24 hours post-dose
  • AddedArea Under the Concentration-Time Curve AUC0-6h, AUC6-12h and AUC0-12h of M1Time frame: 0 to 12 hours post-dose
  • AddedArea Under the Concentration-Time Curve AUC12-18h and AUC12-24h of M1Time frame: 12 to 24 hours post-dose
  • AddedArea Under the Concentration-Time Curve AUC18-24h of M1Time frame: 18 to 24 hours post-dose
  • AddedTime to Maximum Concentration (Tmax) of M1Time frame: 0 to 24 hours post-dose
  • AddedArea Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of M1Time frame: 0 to 24 hours post-dose
  • AddedMaximum Concentration (Cmax) of Insulin GlargineTime frame: 0 to 24 hours post-dose
  • AddedArea Under the Concentration-Time Curve AUC0-12h and AUC0-24h of Insulin GlargineTime frame: 0 to 24 hours post-dose
  • AddedArea Under the Concentration-Time Curve AUC0-6hr of Insulin GlargineTime frame: 0 to 6 hours post-dose
  • AddedArea Under the Concentration-Time Curve AUC6-12h of Insulin GlargineTime frame: 6 to 12 hours post-dose
  • AddedArea Under the Concentration-Time Curve AUC12-18h of Insulin GlargineTime frame: 12 to 18 hours post-dose
  • AddedArea Under the Concentration-Time Curve AUC18-24h of Insulin GlargineTime frame: 18 to 24 hours post-dose
  • AddedArea Under the Concentration-Time Curve AUC12-24h of Insulin GlargineTime frame: 12 to 24 hours post-dose
  • AddedTime to Maximum Concentration (Tmax) of Insulin GlargineTime frame: 0 to 24 hours post-dose
  • AddedArea Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Insulin GlargineTime frame: 0 to 24 hours post-dose
  • AddedGIRAUC0-24h, GIRAUC0-end of Clamp up to 24hours, GIRAUC0-6h, GIRAUC0-12hTime frame: 0 to 24 hours post-dose
  • AddedGIRAUC0-∞Time frame: 0 to 24 hours post-dose
  • AddedGIRAUC6-12hTime frame: 6 to 12 hours post-dose
  • AddedGIRAUC12-18h and GIRAUC12-24hTime frame: 12 to 24 hours post-dose
  • AddedGIRAUC18-24hTime frame: 18 to 24 hours post-dose
  • AddedGIRmaxTime frame: 0 to 24 hours post-dose
  • AddedTime to GIRmaxTime frame: 0 to 24 hours post-dose
  • AddedTotal Amount of Glucose Infused During Clamp Procedure (Gtot)Time frame: 0 to 24 hours post-dose
  • RemovedTo evaluate additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargineTime frame: 60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose
  • RemovedTo evaluate additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for M1Time frame: 60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose
  • RemovedTo compare the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.Time frame: Time Frame: 60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose
  • RemovedTo assess the safety of NKF-INS(G)Time frame: Day 1 to 7 weeks
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore To compare the Pharmacokinetic (PK) of NKF-INS Glargine(G) to United States (US)-approved and European Union (EU)-authorized Lantus to demonstrate PK similarity for metabolite 21A-Gly-human insulin (M1)Now Area Under the M1 Concentration-Time Curve From 0 to 12 Hours (AUC0-12h of M1)Time frame: 60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose → 0 to 12 hours post-dose
    Secondary outcomes 23 added, 4 removed
    What changed in the outcomes
    • AddedMaximum Capacity (Cmax) of M1Time frame: 0 to 24 hours post-dose
    • AddedArea Under the Concentration-Time Curve AUC0-6h, AUC6-12h and AUC0-12h of M1Time frame: 0 to 12 hours post-dose
    • AddedArea Under the Concentration-Time Curve AUC12-18h and AUC12-24h of M1Time frame: 12 to 24 hours post-dose
    • AddedArea Under the Concentration-Time Curve AUC18-24h of M1Time frame: 18 to 24 hours post-dose
    • AddedTime to Maximum Concentration (Tmax) of M1Time frame: 0 to 24 hours post-dose
    • AddedArea Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of M1Time frame: 0 to 24 hours post-dose
    • AddedMaximum Concentration (Cmax) of Insulin GlargineTime frame: 0 to 24 hours post-dose
    • AddedArea Under the Concentration-Time Curve AUC0-12h and AUC0-24h of Insulin GlargineTime frame: 0 to 24 hours post-dose
    • AddedArea Under the Concentration-Time Curve AUC0-6hr of Insulin GlargineTime frame: 0 to 6 hours post-dose
    • AddedArea Under the Concentration-Time Curve AUC6-12h of Insulin GlargineTime frame: 6 to 12 hours post-dose
    • AddedArea Under the Concentration-Time Curve AUC12-18h of Insulin GlargineTime frame: 12 to 18 hours post-dose
    • AddedArea Under the Concentration-Time Curve AUC18-24h of Insulin GlargineTime frame: 18 to 24 hours post-dose
    • AddedArea Under the Concentration-Time Curve AUC12-24h of Insulin GlargineTime frame: 12 to 24 hours post-dose
    • AddedTime to Maximum Concentration (Tmax) of Insulin GlargineTime frame: 0 to 24 hours post-dose
    • AddedArea Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Insulin GlargineTime frame: 0 to 24 hours post-dose
    • AddedGIRAUC0-24h, GIRAUC0-end of Clamp up to 24hours, GIRAUC0-6h, GIRAUC0-12hTime frame: 0 to 24 hours post-dose
    • AddedGIRAUC0-∞Time frame: 0 to 24 hours post-dose
    • AddedGIRAUC6-12hTime frame: 6 to 12 hours post-dose
    • AddedGIRAUC12-18h and GIRAUC12-24hTime frame: 12 to 24 hours post-dose
    • AddedGIRAUC18-24hTime frame: 18 to 24 hours post-dose
    • AddedGIRmaxTime frame: 0 to 24 hours post-dose
    • AddedTime to GIRmaxTime frame: 0 to 24 hours post-dose
    • AddedTotal Amount of Glucose Infused During Clamp Procedure (Gtot)Time frame: 0 to 24 hours post-dose
    • RemovedTo evaluate additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for insulin glargineTime frame: 60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose
    • RemovedTo evaluate additional PK parameters of NKF-INS(G), US-approved and EU-authorized Lantus to demonstrate similarity for M1Time frame: 60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose
    • RemovedTo compare the Pharmacodynamic (PD) of NKF-INS(G) to US-approved and EU-authorized Lantus by examining glucose infusion rate (GIR) profiles after a single subcutaneous (SC) dose.Time frame: Time Frame: 60 and 0 minutes pre-dose and 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours post-dose
    • RemovedTo assess the safety of NKF-INS(G)Time frame: Day 1 to 7 weeks
    + 3 other changes: index terms, verification date and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06627478
Lead sponsor
Xentria, Inc.
Responsible party
Sponsor
First posted
Oct 4, 2024
Start date
Oct 29, 2024
Primary completion
Jul 3, 2025
Completion
Jul 3, 2025
Results posted
Oct 23, 2026
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion